165 related articles for article (PubMed ID: 15838657)
21. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
Krainer M; Tomek S; Elandt K; Horak P; Albrecht W; Eisenmenger M; Höltl W; Schramek P; Stackl W; Zielinski C; Reibenwein J
J Urol; 2007 Jun; 177(6):2141-5; discussion 2145. PubMed ID: 17509302
[TBL] [Abstract][Full Text] [Related]
22. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer.
Safarinejad MR
Urol Oncol; 2005; 23(2):93-101. PubMed ID: 15869993
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Ferrero JM; Chamorey E; Oudard S; Dides S; Lesbats G; Cavaglione G; Nouyrigat P; Foa C; Kaphan R
Cancer; 2006 Aug; 107(4):738-45. PubMed ID: 16826591
[TBL] [Abstract][Full Text] [Related]
24. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW
Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.
Kolodziej M; Neubauer MA; Rousey SR; Pluenneke RE; Perrine G; Mull S; Boehm KA; Ilegbodu D; Asmar L
Clin Genitourin Cancer; 2006 Sep; 5(2):155-61. PubMed ID: 17026805
[TBL] [Abstract][Full Text] [Related]
26. Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients.
Miyoshi Y; Uemura H; Nakamura M; Hasumi H; Sugiura S; Makiyama K; Nakaigawa N; Kishida T; Ogawa T; Yao M; Kubota Y
Int J Clin Oncol; 2005 Jun; 10(3):182-6. PubMed ID: 15990966
[TBL] [Abstract][Full Text] [Related]
27. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
Lin AM; Rini BI; Derynck MK; Weinberg V; Park M; Ryan CJ; Rosenberg JE; Bubley G; Small EJ
Clin Genitourin Cancer; 2007 Jun; 5(5):323-8. PubMed ID: 17645829
[TBL] [Abstract][Full Text] [Related]
28. Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: an Italian clinical experience.
Cicero G; De Luca R
Eur Rev Med Pharmacol Sci; 2011 Mar; 15(3):325-31. PubMed ID: 21528780
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
[TBL] [Abstract][Full Text] [Related]
30. Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
Protheroe A
Nat Clin Pract Oncol; 2005 Feb; 2(2):68-9. PubMed ID: 16264873
[No Abstract] [Full Text] [Related]
31. Vinorelbine-based chemotherapy in hormone-refractory prostate cancer.
Zampino MG; Verri E; Locatelli M; Curigliano G; Ascione G; Sbanotto A; Rocca A; Verweij F; Matei V; Scardino E; Decobelli O; Goldhirsch A; Nolè F
Anticancer Res; 2006; 26(3B):2375-80. PubMed ID: 16821619
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer.
Campone M; Blasinska-Morawiec M; Tekiela A; Koralewski P; Pouget JC; Douville I; Brandely M
Cancer Chemother Pharmacol; 2009 Apr; 63(5):937-43. PubMed ID: 18751706
[TBL] [Abstract][Full Text] [Related]
33. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Van Poppel H
Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
[TBL] [Abstract][Full Text] [Related]
34. Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
Wada Y; Kikuchi K; Takahashi W; Honda J; Nakanishi J; Matsumoto K; Kuwahara T; Kai N; Kikukawa H; Ueda S
Cancer Chemother Pharmacol; 2008 Jan; 61(1):53-61. PubMed ID: 17375305
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan.
Naito S; Tsukamoto T; Koga H; Harabayashi T; Sumiyoshi Y; Hoshi S; Akaza H
Jpn J Clin Oncol; 2008 May; 38(5):365-72. PubMed ID: 18417502
[TBL] [Abstract][Full Text] [Related]
36. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer.
Goodin S; Medina P; Capanna T; Shih WJ; Abraham S; Winnie J; Doyle-Lindrud S; Todd M; DiPaola RS
J Clin Oncol; 2005 May; 23(15):3352-7. PubMed ID: 15738531
[TBL] [Abstract][Full Text] [Related]
37. Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial.
Nelli F; Naso G; De Pasquale Ceratti A; Saltarelli R; Dauria G; Lugini A; Ferraldeschi R; Picone V; Moscetti L; Cortesi E
J Chemother; 2004 Aug; 16(4):392-9. PubMed ID: 15332716
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer.
Galli L; Fontana A; Galli C; Landi L; Fontana E; Antonuzzo A; Andreuccetti M; Aitini E; Barbieri R; Di Marsico R; Falcone A
Br J Cancer; 2007 Dec; 97(12):1613-7. PubMed ID: 18026196
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
[TBL] [Abstract][Full Text] [Related]
40. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
